UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000010579
Receipt number R000012338
Scientific Title Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer.
Date of disclosure of the study information 2013/04/30
Last modified on 2013/04/21 13:18:36

No. Disposal Last modified on Item of update
1 Insert 2013/04/24 00:04:09